Capital Fund Management (CFM)
NTLA icon

Capital Fund Management (CFM)’s Intellia Therapeutics NTLA Stock Holding History

Capital Fund Management (CFM)’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$518K Sell
40,400
-161,600
-80% -$2.06M ﹤0.01% 1869
2025
Q4 		$1.82M Buy
202,000
+16,400
+9% +$226K 0.01% 1748
2025
Q3 		$3.21M Sell
185,600
-83,100
-31% -$1.02M 0.01% 1526
2025
Q2 		$2.52M Buy
268,700
+104,600
+64% +$859K 0.01% 1548
2025
Q1 		$1.17M Buy
164,100
+120,000
+272% +$1.21M ﹤0.01% 1614
2024
Q4 		$514K Buy
+44,100
New +$688K ﹤0.01% 1904
2024
Q3 		– Sell
-44,000
Closed -$985K – 2097
2024
Q2 		$985K Sell
44,000
-53,100
-55% -$1.26M ﹤0.01% 1609
2024
Q1 		$2.67M Buy
97,100
+19,700
+25% +$547K 0.01% 1315
2023
Q4 		$2.36M Buy
77,400
+52,600
+212% +$1.51M 0.01% 1458
2023
Q3 		$784K Buy
+24,800
New +$962K ﹤0.01% 1713

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Capital Fund Management (CFM)'s NTLA Position: Q1 2026 in Review

Capital Fund Management (CFM) increased its Intellia Therapeutics (NTLA) stake by 278% in Q1 2026, buying an estimated $6.84M and bringing the position to 730,122 shares worth $9.36M. The position accounts for 0.04% of the portfolio, ranked #580.

Capital Fund Management (CFM) first reported a position in NTLA in Q4 2022 and has held it in 9 quarters since. 303 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

  • Capital Fund Management (CFM) held 730,122 shares of Intellia Therapeutics worth $9.36M as of Q1 2026.
  • Capital Fund Management (CFM) bought 537,096 Intellia Therapeutics shares in Q1 2026, an estimated $6.84M.
  • Intellia Therapeutics made up 0.04% of Capital Fund Management (CFM)'s portfolio in Q1 2026, its #580 holding.
  • Capital Fund Management (CFM) first reported a position in Intellia Therapeutics in Q4 2022 and has held it in 9 quarters since.
  • 303 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on Capital Fund Management (CFM)'s 13F filing for Q1 2026, filed 14 May 2026.